Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

Inge M. W. Verberk*, Els O. Misdorp, Jannet Koelewijn, Andrew J. Ball, Kaj Blennow, Jeffrey L. Dage, Noelia Fandos, Oskar Hansson, Christophe Hirtz, Shorena Janelidze, Sungmin Kang, Kristopher Kirmess, Jana Kindermans, Ryan Lee, Matthew R. Meyer, Dandan Shan, Leslie M. Shaw, Teresa Waligorska, Tim West, Henrik ZetterbergRebecca M. Edelmayer, Charlotte E. Teunissen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Introduction: Pre-analytical sample handling might affect the results of Alzheimer's disease blood-based biomarkers. We empirically tested variations of common blood collection and handling procedures. Methods: We created sample sets that address the effect of blood collection tube type, and of ethylene diamine tetraacetic acid plasma delayed centrifugation, centrifugation temperature, aliquot volume, delayed storage, and freeze–thawing. We measured amyloid beta (Aβ)42 and 40 peptides with six assays, and Aβ oligomerization-tendency (OAβ), amyloid precursor protein (APP)699-711, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), total tau (t-tau), and phosphorylated tau181. Results: Collection tube type resulted in different values of all assessed markers. Delayed plasma centrifugation and storage affected Aβ and t-tau; t-tau was additionally affected by centrifugation temperature. The other markers were resistant to handling variations. Discussion: We constructed a standardized operating procedure for plasma handling, to facilitate introduction of blood-based biomarkers into the research and clinical settings.
Original languageEnglish
JournalAlzheimer's and Dementia
Early online date2021
Publication statusE-pub ahead of print - 2021

Cite this